FDA explains plans to bolster cell and gene therapy approvals through wider messaging
Regulatory NewsJoanne S. Eglovitch.png.aspx?lang=en-us&width=350&height=197&ext=.png)
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceHealth Authority meeting and communication strategyNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy